These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25267750)

  • 81. Case of severe ulceration induced by pazopanib.
    Goto H; Niwakawa M; Yoshikawa S; Otsuka M; Omodaka T; Yoshimi K; Kiyohara Y
    J Dermatol; 2017 Apr; 44(4):474-476. PubMed ID: 27238880
    [No Abstract]   [Full Text] [Related]  

  • 82. Rapid and life-threatening heart failure induced by pazopanib.
    Wang H; Rodriguez-Pla A; Campagna A
    BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30115717
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Abnormal hair].
    Coen M; Cramer B; Serratrice J
    Rev Med Interne; 2019 Feb; 40(2):134-135. PubMed ID: 29054584
    [No Abstract]   [Full Text] [Related]  

  • 84. Reply to B. Rini et al and S. Buti et al.
    Choueiri TK; Halabi S; Morris MJ; George D
    J Clin Oncol; 2017 Jun; 35(16):1859-1860. PubMed ID: 28549224
    [No Abstract]   [Full Text] [Related]  

  • 85. Editorial Comment from Dr Porta et al. to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.
    Porta C; Cosmai L; Previtali P
    Int J Urol; 2017 Apr; 24(4):279-280. PubMed ID: 28399614
    [No Abstract]   [Full Text] [Related]  

  • 86. Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol. 2022;81:576-85.
    Montorsi F; Capitanio U; Rosiello G; Larcher A
    Eur Urol; 2022 Jun; 81(6):e149. PubMed ID: 35282969
    [No Abstract]   [Full Text] [Related]  

  • 87. Gastric candidiasis developing after administration of potassium-competitive acid blocker.
    Kato S; Akasaka T; Kawamoto Y; Mori K; Ishida H
    Gastrointest Endosc; 2019 Nov; 90(5):847-848. PubMed ID: 31220443
    [No Abstract]   [Full Text] [Related]  

  • 88. Reply to M. Horiguchi et al.
    Paul J; Kelly C; Stobo J; Powles T
    J Clin Oncol; 2017 Oct; 35(29):3373-3374. PubMed ID: 28800270
    [No Abstract]   [Full Text] [Related]  

  • 89. Comments to the editor concerning the paper entitled "Preclinical renal cancer chemopreventive efficacy of geraniol by modulation of multiple molecular pathways" Shiekh Tanveer Ahmad et al.
    Vuch J; Marcuzzi A; Zanin V; Crovella S
    Toxicology; 2012 Mar; 293(1-3):123-124. PubMed ID: 22210290
    [No Abstract]   [Full Text] [Related]  

  • 90. Reply to Barni et al.
    Miceli Sopo S; Sinatti D; Gelsomino M
    Pediatr Allergy Immunol; 2021 Oct; 32(7):1590. PubMed ID: 34037284
    [No Abstract]   [Full Text] [Related]  

  • 91. Response to Bellini et al.
    Wald A; Bharucha AE; Malcolm A; Remes-Troche JM
    Am J Gastroenterol; 2022 May; 117(5):809-810. PubMed ID: 35315800
    [No Abstract]   [Full Text] [Related]  

  • 92. Reply to A. Vickers et al.
    Jayadevappa R; Chhatre S; Gallo JJ; Wittink MN; Morales KH; Lee DI; Guzzo T; Vapiwala N; Wong YN; Newman DK; Van Arsdalen K; Malkowicz SB; Schwartz JS; Wein AJ
    J Clin Oncol; 2019 Dec; 37(35):3463-3464. PubMed ID: 31566992
    [No Abstract]   [Full Text] [Related]  

  • 93. Reply to K. Lisy et al.
    Wallner LP; Katz SJ; Hawley ST
    J Clin Oncol; 2017 Dec; 35(34):3891. PubMed ID: 29023214
    [No Abstract]   [Full Text] [Related]  

  • 94. Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition.
    Kawakami M; Mustachio LM; Zheng L; Chen Y; Rodriguez-Canales J; Mino B; Kurie JM; Roszik J; Villalobos PA; Thu KL; Silvester J; Cescon DW; Wistuba II; Mak TW; Liu X; Dmitrovsky E
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10810-E10811. PubMed ID: 30377273
    [No Abstract]   [Full Text] [Related]  

  • 95. Reply to K. Masuda et al.
    Fennell DA; Taylor P; Gilligan D; Nakano T; Scherpereel A; Pavlakis N; van Meerbeeck JP; Aerts JGJV; Nowak AK; Kindler H; Baas P
    J Clin Oncol; 2019 Sep; 37(25):2294-2295. PubMed ID: 31329517
    [No Abstract]   [Full Text] [Related]  

  • 96. Response by Pei et al. to letters regarding article, "Pharmacokinetic study of imrecoxib in patients with renal insufficiency".
    Pei Q; Xie JL; Zhang H; Yang GP
    Eur J Clin Pharmacol; 2020 Mar; 76(3):473-474. PubMed ID: 31897531
    [No Abstract]   [Full Text] [Related]  

  • 97. Reply to Jin
    Boucly A; Weatherald J; Savale L; Jaïs X; Montani D; Humbert M; Sitbon O
    Am J Respir Crit Care Med; 2021 Dec; 204(12):1494-1495. PubMed ID: 34672868
    [No Abstract]   [Full Text] [Related]  

  • 98. Reply to S. Sorscher.
    Rose BS; Winer EP; Mamon HJ
    J Clin Oncol; 2017 May; 35(15):1746-1747. PubMed ID: 28524778
    [No Abstract]   [Full Text] [Related]  

  • 99. Reply to Soman et al, Alffenaar et al, Metcalfe et al, and Raoult.
    Cegielski JP; Chen MP; Tupasi TE; Leimane V; Volchenkov GV;
    Clin Infect Dis; 2015 Mar; 60(6):971-3. PubMed ID: 25527654
    [No Abstract]   [Full Text] [Related]  

  • 100. Reply to Sun et al.: Deposition of organic nitrogen.
    Li Y; Schichtel BA; Walker JT; Schwede DB; Chen X; Lehmann CM; Puchalski MA; Gay DA; Collett JL
    Proc Natl Acad Sci U S A; 2016 Aug; 113(31):E4435. PubMed ID: 27439877
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.